Clinical Trial Update: PS-341 in Treating Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of PS-341 (bortezomib) in patients with advanced cancer has completed, including leukemia and lymphoma cohorts among the listed indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Mayo Clinic | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED